The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

Investigational New Drugs

Volumn 28, Issue 4, 2010, Pages 413-420

  Ma, Brigette B Y ^a   Lui, Vivian W Y ^a   Hui, Edwin P ^a   Lau, Cecilia P Y ^a   Ho, Kakiu ^a   Ng, Margaret H L ^a   Cheng, S H ^a   Tsao, Sai Wah ^b   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AKT; mTOR; Nasopharyngeal carcinoma; RAD001 (everolimus)

Indexed keywords

CISPLATIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; S6 KINASE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL CYCLE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NASOPHARYNGEAL NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 77956620903     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9269-x     Document Type: Article

References (19)

1. Ma BB, Hui EP, Chan AT (2008) Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 99(7):1311-1318. doi:10.1111/j.1349-7006.2008.00836.x (Pubitemid 351761718)
2. Ma BB, Chan AT (2006) Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 6(3):383-394. doi:10.1586/14737140.6.3.383 (Pubitemid 44192920)
3. Liu LZ, Qian G, Shi X, Fang J, Jiang BH (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67(13):6325-6332. doi:10.1158/0008-5472. CAN-06-4261
4. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF (2008) Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 19(2):319-328
5. Morrison JA, Pathmanathan R, Raab-Traub N (2004) Differential signaling pathways are activated in the Epstein-Barr virusassociated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 64(15):5251-5260. doi:10.1158/0008-5472. CAN-04-0538
6. Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, Zeng YX, Zhu XF (2007) Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6(11):1379-1385
7. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X (2007) Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer 120(9):1891-1898. doi:10.1002/ijc.22489 (Pubitemid 46418364)
8. Wangpaichitr M, You M, Kuo MT, Feun L, Lampidis T, Savaraj N (2008) Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591 (1-3): 124-127. doi:10.1016/j.ejphar.2008.06.028
9. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13(14):4261-4270. doi:10.1158/1078- 0432. CCR-06-2770
10. Beuvink I, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747-759. doi:10.1016/j.cell.2004.12.040 (Pubitemid 40568794)
11. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111(1):379-382. doi:10.1182/blood-2007-03-080796
12. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67(6):2408-2413. doi:10.1158/0008-5472. CAN-06-4490
13. O'Reilly KE, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500-1508. doi:10.1158/0008-5472. CAN-05-2925
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456. doi:10.1016/S0140-6736 (08) 61039-9
15. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66(20):10040-10047. doi:10.1158/0008-5472. CAN-06-0802
16. Albert JM, Cao C, Lu B (2006) Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5(5):1183-1189. doi:10.1158/1535-7163. MCT-05-0400
17. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134(5):475-484. doi:10.1111/j.1365-2141.2006.06210.x (Pubitemid 44141713)
18. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2):333-339. doi:10.1038/sj.leu.2404471 (Pubitemid 46158128)
19. Wan X, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932-1940. doi:10.1038/sj.onc.1209990 (Pubitemid 46474636)